SharmaI,SarmaU,DuttaUC, 2014.Pathology of ovarian tumour - A hospital-based study,Int J Medi Sci Clin Invent (IJMSCI) 1 284 -6
AntonC,CarvalhoFM,OliveiraEI,MacielGA,BaracatEC,CarvalhoJP, 2012.A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses,Clinics (Sao Paulo) 67 437 -41
ChoKR,ShihIM. Ovarian,Cancer, 2009.,Annu Rev Pathol 4 287 -313
GropTV,CadronI,DesspierreE,DaemenA,LuenenK,AmanatF, 2011.HE4 and CA125 as a diagnostic test in ovarian cancer prospective validation of the risk of ovarian malignancy algorithm,Br J Cancer 104 863 -70
ThanapprapasrD,Wilailak S, 2012.Screening for ovarian cancer in women, ovarian cancer clinical and therapeutic perspectives, 43 -54
SarojiniS,TamirA,LimH,LiS,ZhangS,GoyA, 2012.Early detection biomarkers for ovarian cancer,J Oncol 1 -15
MooreRG,MillerMC,DiselvestroP,LandrumLM,GanjewskiW,BallJJ, 2011.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass,Obstet Gynecol 118 280 -8
MontagnanaM,DaneseE,RuzzenenteO,BrescianiV,NuzzoT,GelatiM., 2011.The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?,Clin Chem Lab Med 49 521 -5
KobayashiE,UedaY,MatsuzakiS,YokoyamaT,KimuraT,YoshinoK, .Biomarkers for screening, diagnosis, and monitoring of ovarian cancer [internet],2012 September 7 -
BandieraE,RomaniC,SpecchiaC,ZanottiL,GalliC,RuggeriG, 2011.Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management,Cancer Epidemiol Biomarkers Prev 20 2496 -506
SchimnichAA, 2013.A Review of current serum markers and their clinical applications, -
BastRC,SkatesS,LokshinA,MooreRG, 2012.Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers,Int J Gynecol Cancer 22 S5 -8
MooreRG,Jabre-RaughleyM,BrownAK, 2010.Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass,Am J Obstet Gynecol 203 228 -
KadijaS,StefanovicA,JeremicK., 2012.The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis,Int J Gynecol Cancer 22 238 -44
KarlsenMA,SandhuN,HøgdallC, 2012.Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass,Gynecol Oncol 127 379 -83
MooreRG,HawkinsDM,MillerMC,LandrumLM,GajewskiW,BallJJ, 2014.Combining clinical assessment and the risk of ovarian malignancy algorithm for the prediction of ovarian cancer,Gynecol Oncol 135 547 -51
RuggeriG,BandieraE,ZanottiL. HE4, 2011.and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm,Clinica Chimica Acta 412 1447 -53
HellströmI,RaycraftJ,Hayden-LedbetterM,LedbetterJA,SchummerM,McIntoshM, 2003.The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,Cancer Res 63 3695 -700
Van GorpT,VeldmanJ,Van CalsterB,CadronI,LeunenK,AmantF, 2012.Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses,Eur J Cancer 48 1649 -56
Al MusalhiK,Al KindiM,Al AisaryF,RamadhanF,Al RawahiT,Al HataliK, 2016.Risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass,Oman Med J 31 336 -44
SimmonsAR,BaggerlyK,BastRC, 2013.The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas,Oncology 27 548 -56